Trending menu:
News
-
21 November 2019
Sierra Oncology initiates study of momelotinib in myelofibrosis
Sierra Oncology has initiated a Phase III clinical trial to assess its investigational JAK1, JAK2 and ACVR1 inhibitor, momelotinib, for the treatment of myelofibrosis.
-
21 November 2019
Hope Biosciences to trial stem cell therapy for Alzheimer’s
Hope Biosciences has secured US Food and Drug Administration (FDA) approval to study its autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) in a Phase I/II trial for Alzheimer’s.
-
21 November 2019
BMS’ CheckMate -915 trial fails to meet one co-primary endpoint
Bristol-Myers Squibb (BMS) has reported that the CheckMate -915 study of Opdivo (nivolumab) and Yervoy (ipilimumab) combination failed to meet one of the co-primary endpoints in patients with melanoma.
-
20 November 2019
MD Connect unveils PatientCentra division for patient recruitment
MD Connect has launched a new division called PatientCentra, which will focus on technology-driven and patient-centric approach towards recruitment in clinical trials.
-
20 November 2019
Vertex-CRISPR’s CTX001 shows positive outcomes in trial patients
Vertex Pharmaceuticals and CRISPR Therapeutics have reported positive interim results from two Phase I/II clinical trials of investigational, ex-vivo, CRISPR/Cas9 gene-edited therapy, CTX001.
-
20 November 2019
Allergan’s migraine drug yields positive data in Phase III trial
Allergan has reported positive data from the Phase III ACHIEVE II (UBR-MD-02) trial of ubrogepant for the acute treatment of patients with migraine.
-
20 November 2019
Morphosys to enrol more patients in tafasitamab’s B-MIND trial
Morphosys has said that an independent data monitoring committee (IDMC) recommended increasing the size of tafasitamab’s Phase III B-MIND clinical trial.
-
19 November 2019
Evolution Research and Invicro to offer clinical research services
Evolution Research Group (ERG) and Konica Minolta’s Invicro have collaborated to provide early-to-late-phase clinical research services for biotech and pharma sponsors.
-
19 November 2019
Merck says vericiguat’s VICTORIA trial met primary endpoint
Merck has reported that the Phase III VICTORIA clinical trial of vericiguat met its primary efficacy endpoint in patients suffering from worsening chronic heart failure with reduced ejection fraction (HFrEF).
-
19 November 2019
Valneva chikungunya vaccine shows promise in Phase I trial
French biotech company Valneva has announced positive data from the Phase I clinical trial of its chikungunya vaccine candidate, VLA1553.